SJ

Samantha Jérusalmy

Partner at Elaia Partners

Paris, Île-de-France

Invests in

Locations:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Skills

Entrepreneurship
Private Equity
Venture Capital
Start-ups
Corporate Finance
Business Modeling
Business Strategy
Financial Modeling
Investment Banking
Management Consulting
Investments
E-commerce
Valuation
Business Planning
Due Diligence
Business Development
Strategy
Financial Analysis
Market Analysis
Corporate Development

Work Experience

  • Partner

    2014

    Elaia manages over €700m and invests in early stage B2B tech-intensive startups. Elaia diversified portfolio includes companies such as Mirakl, Criteo, Shift Technology, Ornikar, IbanFirst, The Hotel Network, Zenchef, Aqemia, Sim&Cure, Tilak etc. More on http://www.elaia.com

  • Investment Manager

    2011 - 2014

  • Analyst

    2008 - 2011

2024

  • Board Observer

    2024

    Doccla is a leader in multi-pathology remote monitoring across Europe. It is a trusted partner of 50% of NHS healthcare facilities in the UK and operates in nine other European countries. Doccla has already accumulated 4m daily patients and a NPS of over 70, indicating very high patient satisfaction.

2024

  • Board Member

    2024

    Adomik collects the advertising data from all your ad servers, SSPs, header partners to deliver insights that make your programmatic business thrive.

  • Board Member

    2022

    LynxCare is an AI-powered Big Data platform enabling hospitals to mine their legacy data, to improve clinical efficiency and higher the quality of care.

  • Board Member

    2021

    Digital therapeutics pioneer specializing in the development of mobile medical application games used as monitoring and rehabilitation tools for chronic diseases.

2020

  • Board Member

    2020

    inHEART is committed to delivering the world’s most sophisticated, AI-enabled, digital twin of the heart to advance the care of patients living with cardiac disease

  • Board Member

    2019

    Sim&Cure is a digital start-up focused on improving neurovascular treatments of cerebral aneurysm with a proprietary software suite (Class IIa medical device with CE mark and FDA 510k cleared) that has already been used to treat more than 10,000 patients in 500+ hospitals.

  • Board Member

    2018

    SaaS-based Location Intelligence solution that helps professionals from the retail, real estate, and FMCG industries make informed decisions about their business strategies. Mytraffic acquires Geoblink. They are joining forces to help businesses globally, build better strategies with traffic analytics and geospatial intelligence.

2020 - 2022

  • Board Member

    2020 - 2022

    Sold to Global Blue

2013 - 2022

  • Board Member

    2013 - 2022

    Sold to PSG